21.93
0.23 (1.06%)
| Penutupan Terdahulu | 21.70 |
| Buka | 21.74 |
| Jumlah Dagangan | 6,823,612 |
| Purata Dagangan (3B) | 7,982,650 |
| Modal Pasaran | 15,252,130,816 |
| Harga / Jualan (P/S) | 788.72 |
| Harga / Buku (P/B) | 3.66 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 9 Feb 2026 |
| Margin Operasi (TTM) | -4,823.84% |
| EPS Cair (TTM) | -0.750 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -16.10% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | -96.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.93% |
| Nisbah Semasa (MRQ) | 33.47 |
| Aliran Tunai Operasi (OCF TTM) | -839.45 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -375.20 M |
| Pulangan Atas Aset (ROA TTM) | -10.73% |
| Pulangan Atas Ekuiti (ROE TTM) | -12.54% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Roivant Sciences Ltd. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 2.0 |
| Purata | 1.30 |
|
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Growth |
| % Dimiliki oleh Orang Dalam | 30.31% |
| % Dimiliki oleh Institusi | 83.49% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 33.00 (Goldman Sachs, 50.48%) | Beli |
| Median | 29.00 (32.24%) | |
| Rendah | 26.00 (HC Wainwright & Co., 18.56%) | Beli |
| 26.00 (Citigroup, 18.56%) | Beli | |
| Purata | 29.25 (33.38%) | |
| Jumlah | 4 Beli | |
| Harga Purata @ Panggilan | 21.70 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Goldman Sachs | 15 Dec 2025 | 33.00 (50.48%) | Beli | 21.90 |
| Leerink Partners | 15 Dec 2025 | 32.00 (45.92%) | Beli | 21.90 |
| HC Wainwright & Co. | 12 Dec 2025 | 26.00 (18.56%) | Beli | 22.10 |
| Citigroup | 11 Nov 2025 | 26.00 (18.56%) | Beli | 20.90 |
| 29 Oct 2025 | 25.00 (14.00%) | Beli | 18.76 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| VENKER ERIC | - | 22.16 | -200,000 | -4,432,000 |
| Jumlah Keseluruhan Kuantiti Bersih | -200,000 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -4,432,000 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 22.16 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| VENKER ERIC | Pegawai | 12 Jan 2026 | Jual (-) | 200,000 | 22.16 | 4,432,000 |
| VENKER ERIC | Pegawai | 12 Jan 2026 | Pelaksanaan pilihan | 200,000 | - | - |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 11 Dec 2025 | Pengumuman | Roivant Highlights Continued Pipeline Progress and Outlook for Company’s Next Phase of Growth at 2025 Investor Day |
| 10 Nov 2025 | Pengumuman | Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update |
| 27 Oct 2025 | Pengumuman | Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |